Financial Performance - Cryoport's Q3 2025 revenue reached $4423 million, a 15% year-over-year increase[8, 13] - Life Sciences Services revenue increased by 16% to $24258 million in Q3 2025[11, 13] - Life Sciences Products revenue increased by 15% to $19975 million in Q3 2025[11, 13] - BioServices & Biostorage revenue increased by 21% in Q3 2025[11] - Commercial Cell & Gene Therapy revenue grew by 36% year-over-year to $83 million in Q3 2025[8, 11, 17] - Cryoport revised its full-year 2025 revenue guidance to $170 - $174 million[8] - Cryoport has $421 million in cash and short-term investments[8, 15] - Gross margin from continuing operations was 482%[15, 26] - Adjusted EBITDA from continuing operations was $(06) million[15] Operational Highlights - Cryoport supports 19 commercial Cell & Gene Therapies[8, 21] - Cryoport supports 745 active Cell & Gene Therapy clinical trials[8, 20, 24] - Cryoport supports 83 Phase III clinical trials[18, 20] - Cryoport supports approximately 70% of all industry clinical trials[24]